Top Industry And Financial Leaders to Explore Key Business Issues Impacting The Biotech Industry At BIO’s CEO & Investor Conference

WASHINGTON, D.C. (February 7, 2007) -- Important trends and questions in today’s biotechnology business environment will be addressed in the Business Roundtable sessions at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2007, to be held February 12-14 at the Waldorf=Astoria Hotel in New York City.  The meeting is co-hosted by Rodman and Renshaw, Jeffries, CIBC, Bank of America, Think Equity Partners LLC, and Pacific Growth Equities.

Now in its ninth year, the BIO CEO & Investor Conference will focus on the central theme “Investing in Biotechnology: The Value, The Risks, The Rewards.”  The event brings together senior biotechnology executives, institutional investors, industry analysts, venture capitalists, investment bankers and other industry executives as they learn about top trends and help shape the future investment landscape of the biotechnology industry.

Just a few of the “can’t miss” Business Roundtable sessions scheduled for the investor conference include:

·              Doing a Transformative Deal
Monday, February 12, 2007, 9:30AM
This panel explores the many ways a company can "transform" itself and achieve subsequent valuations.  Moderated by Paul DeStefano; Prinicpal, Fish & Richardson P.C..

·              IPOs and Alternative Exit Strategies – Is the Glass Half Full, or Half Empty?
Monday, February 12, 2007, 3:30PM
This panel looks at the struggles and successes in IPOs in 2006, lessons learned, and what to expect in the coming years as the fickle IPO window opens and closes.  Moderated by Kevin T. Collins; Shareholder, HellerEhrman LLP.

·              Managing Risk in Clinical Trials – Perspectives and Challenges
Wednesday, February 14, 2007, 9:00AM
Focusing on informed consent, protocol deviations, adverse event reporting, and other issues, this panel examines the legal and regulatory concerns associated with innovations in clinical trial design and the role that insurance plays in process intervention and compliance.  Moderated by Mary Beth Borgwing; Senior Vice President, NY Life Sciences Practice Leader, Willis Group Holdings.

·              The Anatomy of a Deal – Dissecting Bio-Bucks
Wednesday, February 14, 2007, 9:00AM
Panelists will discuss the details and trends of biotech deals, specifically looking at the anatomy--upfront funds, rights, royalties, equity investments, etc.  Moderated by Mr. Tracy Lefteroff; PricewaterhouseCoopers LLP, Life Sciences Industry Services, Life Sciences Industry Services.

For a complete listing of Business Roundtable sessions, as well as the full program for the BIO CEO & Investor Conference, please visit

Advance media registration for the BIO CEO & Investor Conference 2007 is now available online. Registration is complimentary for credentialed members of the news media. To register, please visit  Only reporters and editors working full-time for print or broadcast news organizations may register onsite with valid media credentials. All freelancers and online publications must register in advance by Friday, February 9, 2007. 

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

Upcoming BIO Events

BIO CEO & Investor Conference
Feb. 12-14, 2007
New York City

2007 World Congress on Industrial Biotechnology and Bioprocessing
March 21-24, 2007
Orlando, FL

BIO International Convention
May 6-9, 2007
Boston, MA